01Identity
What is it?
The selected intervention may be observation, silicone-based care, a medicine, an injectable, a device or surgery; each has its own material and risk profile.
Scar Treatment · Aesthetic Medicine · Istanbul
Scar Treatment · Aesthetic Medicine · Istanbul
Scar Treatment
A scar is not one diagnosis. Atrophic, hypertrophic, keloid, contracted, pigmented, tethered, symptomatic and actively inflamed scars behave differently; maturity, cause, location and skin type guide the sequence of care.
The aim is a defined change in symptoms, colour, contour, texture or movement. Complete erasure or restoration to normal uninjured skin is not promised.
Quick Orientation
Identity · composition · preparation · route
The treatment name is only the start of the medical description.
A responsible discussion identifies the exact preparation or device, how it was made, where it is intended to act and which clinical question is being assessed.
02Production
How is it prepared?
For any product or device, formulation, manufacturer, settings or preparation, sterility, maintenance and labelled use are checked separately.
03Route
How does it reach tissue?
Treatment may act on the surface, within scar tissue, across tethering planes or through surgical revision; route follows the diagnosed scar feature.
04Target
What is the clinical target?
Pain, itch, thickness, tethering, colour, contour or restricted movement is selected as the clinical target rather than a promise to remove the scar.
Method Boundary
Scar treatment is a staged plan, not one product
Scar morphology, maturity, cause and function determine the intervention.
The intended role, product identity and target tissue stay visible so unlike procedures are not presented as one interchangeable class.
What may be considered
- Classify the scar and prioritise symptoms or function
- Select a staged option for one scar feature
- Use comparable photographs and symptom measures
- Reassess recurrence, pigment and healing before escalation
What must not be inferred
- Recommend one method for every scar type
- Return scar tissue to normal uninjured skin
- Guarantee colour match, flattening or permanence
- Ignore the underlying disease, tension or ongoing inflammation
A scar that is changing rapidly, ulcerated, infected, unusually painful or diagnostically uncertain needs medical assessment before aesthetic treatment.
Medical Suitability
Clinical question before method selection
Five checks precede any personal decision.
The scar is examined for morphology, maturity, activity, anatomical tension, skin type, symptoms, previous treatment and the condition that caused it.
- 01
Classify morphology
Atrophic, rolling, boxcar, ice-pick, hypertrophic, keloid and contracted patterns are not interchangeable.
- 02
Assess time and activity
Age, growth, redness, itch, pain and ongoing inflammation show whether the scar is still evolving.
- 03
Review cause and anatomy
Acne, surgery, trauma, burn, infection, movement, tension and tethering may alter the plan.
- 04
Review healing and pigment risk
Skin type, keloid tendency, medicines, immune factors and previous pigment change affect suitability.
- 05
Choose the first objective
Symptom control, movement, thickness, colour or contour is prioritised and alternatives are compared.
Product and Treatment Path
Traceability without a public injection recipe
The chosen method must match one diagnosed scar feature.
Surface care, injection, energy, release of tethering and surgery act differently. Their materials, wound burden and recurrence risks remain separate.
01Diagnosis
Morphology and activity
The scar type, maturity, symptoms, cause and anatomical forces are documented first.
- Classify the scar
- Identify active drivers
- Set one clinical priority
02Method
Product, device or surgery
The selected intervention is identified by its material, route, intended tissue and evidence.
- Verify product or device
- Match route to scar feature
- Plan pigment and wound protection
03Sequence
Healing and reassessment
Only one justified step is followed through healing before another method is added.
- Record the baseline
- Review wound and pigment response
- Stop or adapt before escalation
This page does not select a medicine, concentration, injection plan, device setting, depth, surgical technique or combination protocol.
Evidence and Limits
Read the data at product and indication level
Scar morphology determines which evidence is relevant.
Trials use different scar types, scales, devices, medicines and follow-up periods. Improvement in one feature does not mean scar removal.
Match scar type
Evidence for atrophic acne scars does not automatically apply to hypertrophic, keloid, burn or surgical scars.
Match the outcome
Pain, thickness, colour, depth and patient-reported appearance are separate endpoints.
Account for maturity
New and mature scars may respond differently and recurrence can extend beyond short follow-up.
Read combinations cautiously
A multimodal study does not reveal the contribution or safety of every component for every patient.
Available evidence supports selective, staged care; it does not establish one best method or complete, permanent scar disappearance.
Individual Plan
One indication · one traceable intervention · one review point
One scar feature is prioritised at a time.
Baseline morphology, symptoms, function and photographs define the first intervention and the point at which it should be stopped or changed.
Stabilise active disease
Ongoing acne, inflammation, infection or wound problems are addressed before texture-focused treatment.
Choose the first target
Pain, itch, thickness, tethering, colour or contour receives a specific endpoint.
Protect healing
Wound care, sun protection and pigment risk are planned around the selected method.
Reassess recurrence
A raised, painful or enlarging scar is not automatically retreated with greater intensity.
Course and Follow-Up
Expected reaction · adverse effect · clinical endpoint
Healing and scar remodelling unfold on different timelines.
Early redness, crusting or swelling is reviewed separately from later texture, colour, symptom and recurrence outcomes.
- 01Before treatment
Record the baseline
Scar type, dimensions, symptoms, movement and standardised photographs are documented.
- 02Early safety
Protect wound healing
Increasing pain, heat, discharge, ulceration or spreading redness requires in-person review.
- 03Clinical review
Review the chosen feature
Texture, thickness, colour, pain or movement is measured only after appropriate healing.
- 04Decision
Apply the stop rule
Worsening, pigment change, new scarring or recurrence changes the plan rather than triggering escalation.
Risks and Alternatives
Material, anatomy and route shape risk
Every scar intervention can create inflammation or another scar.
Risk depends on skin type, scar biology, anatomical site and the selected medicine, device or surgery.
01Early
Healing and infection
Pain, redness, prolonged healing, infection, ulceration and wound breakdown may occur.
02Skin response
Pigment and texture
Hyperpigmentation, hypopigmentation, persistent redness, atrophy or uneven texture may follow treatment.
03Longer term
Scar worsening
A larger scar, hypertrophic response, keloid recurrence, contracture or new tethering is possible.
04Decision
Withhold or stop
Treatment is withheld or stopped when the indication, consent, safety controls or follow-up cannot support a proportionate plan.
Rapid growth, ulceration, marked pain, discharge, fever or spreading inflammation requires prompt in-person assessment before further scar treatment. Alternatives may include observation, silicone-based scar care, symptom-directed medical treatment, a different device, rehabilitation or surgical review.
Istanbul and Follow-Up
A treatment decision must remain reviewable after travel
Assessment, product records and a local safety route travel together.
International care is not reduced to a treatment day. The in-person examination, exact intervention, early review and later endpoint are connected before departure.
01Before travel
Organise the question
History, previous procedures and the specific scar treatment question prepare the visit without confirming suitability.
02In Istanbul
Examine in person
Anatomy, tissue, active disease, product or device status, risks and alternatives are reviewed together.
03Treatment day
Keep exact records
Product or device identity, batch where relevant, treated region, route and observations remain traceable.
04After return
Arrange review
Expected reactions, stop criteria, local medical access and the later clinical endpoint are agreed before return travel.
The Doctor Aslan Approach
Product-specific, anatomy-led and reversible in decision-making
A scar is treated by type and priority, never by trend.
The plan names the scar morphology, maturity, cause, functional burden and realistic endpoint. The least burdensome defensible step comes first.
Classify first
Atrophic, raised, keloid and contracted scars follow different pathways.
Treat active drivers
Inflammation, tension and ongoing disease are not ignored.
Use staged endpoints
Symptoms, colour, texture and movement are assessed separately.
Accept limits
Improvement may be partial and recurrence or pigment change remains possible.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about scar treatment; no personal protocol or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is Scar Treatment?+
Scar Treatment is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for Scar Treatment?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Classify the scar · choose one priority · reassess healing